Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of <i>BCR::ABL1/A337V</i> Can Be Effectively Overcome with Dasatinib Treatment
Despite the groundbreaking success of tyrosine kinase inhibitor therapy, the management of chronic myeloid leukemia patients is often impaired by resistance due to specific point mutations in the <i>BCR::ABL1</i> oncogene. Upon classical ATP-competitive inhibitor treatment, these single...
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
MDPI AG
2025-02-01
|
| Цуврал: | Current Oncology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.mdpi.com/1718-7729/32/2/97 |